MIRA PHARMACEUTICALS, INC. COMMON STOCK
NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)
最近更新时间: 昨天, 9:55AM0.660
0.01 (1.77%)
AIStockmoo 评分
| 价值 30% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 30% | 2.8 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 3.0 |
| 技术平均移动指标 参考 | 2.5 |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 0.8 |
| 内部交易活动 参考 | NA |
| 机构资金流 参考 | 2.1 |
| 空头持仓 参考 | -2.2 |
| 市场环境 | ×1.00 |
| 宏观环境 参考 | -1.3 |
| 行业对比大市 (6个月) | +10.3% |
| 支柱一致性 | ×1.25 |
| 不计入评分 | |
| 价格波动 参考 | 1.4 |
| 最终评分 | 1.26 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - General (US) | 混合的 | 看涨 |
| Drug Manufacturers - General (全球的) | 混合的 | 看涨 | |
| 股票 | MIRA Pharmaceuticals, Inc. | 混合的 | 混合的 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| MIRA | - | - | - | 3.34 |
| SNY | - | 5.01% | - | 1.40 |
| GILD | - | 1.93% | - | 16.00 |
| AMGN | - | 2.14% | - | 17.60 |
| GRFS | - | 1.07% | - | 0.900 |
| BIIB | - | - | - | 1.94 |
|
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - General |
| 投资方式 | Small Growth |
| 内部持股比例 | 19.68% |
| 机构持股比例 | 5.60% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cross Staff Investments Inc | 30 Sep 2026 | 359,401 |
| First American Bank | 30 Sep 2026 | 60,000 |
该时间范围内无数据。
机构
机构持股比例: 7.43%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 8 | 673,009 |
| 减持 | 12 | 102,950 |
| 新建仓 | 2 | 20,841 |
| 清仓 | 6 | 37,839 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 282,319 | 1.4 |
| 15 Oct 2026 | 349,714 | 2.4 |
| 30 Sep 2026 | 408,844 | 2.4 |
| 15 Sep 2026 | 447,832 | 1.0 |
| 31 Aug 2026 | 205,296 | 4.1 |
| 14 Aug 2026 | 211,083 | 1.5 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 29 Oct 2026 | Yahoo Finance |
Inside Deep Principle: The AI That Runs Its Own Chemistry Experiments to Discover New Materials
HANGZHOU, CHINA / ACCESS Newswire / October 29, 2026 / Inside a lab in Hangzhou, an AI system named Mira recently pushed a single-step reaction's selectivity from 51.82% to 85% in three months, without a chemist manually running the experiments. |
| 29 Oct 2026 | Yahoo Finance |
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment Increase MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc.… |
| 22 Oct 2026 | Yahoo Finance |
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable TolerabilityMIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage… |
| 21 Oct 2026 | Yahoo Finance |
Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients
Modera Wealth Management, LLC ("Modera"), a fee-only wealth management firm serving individuals, families, business owners, and nonprofit organizations, today announced it has launched Mira, a proprietary agentic AI-powered platform. Mira is designed to harmonize data and support tailored financial… |
| 17 Sep 2026 | Yahoo Finance |
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site InitiationMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral… |
| 16 Sep 2026 | Yahoo Finance |
Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
Copper Giant Resources Corp. ("Copper Giant" or the "Company") (TSXV: CGNT) (OTCQX: CGNRF) (FRA: 29H0) today reports the results of an independent geophysical modelling and predictive targeting study completed by Mira Geoscience Ltd. ("Mira") over its Mocoa copper-molybdenum porphyry project in… |
| 01 Sep 2026 | Yahoo Finance |
Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
A landmark clinical study published in Reproductive BioMedicine Online (Bouchard et al., 2026) provides strong diagnostic accuracy validation for at-home quantitative multi-hormone tracking, establishing a major milestone in reproductive healthcare and FemTech. |
| 01 Sep 2026 | Yahoo Finance |
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND SubmissionMIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a… |
投资组合